Filing Details

Accession Number:
0000950170-23-056943
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-31 17:00:11
Reporting Period:
2023-10-27
Accepted Time:
2023-10-31 17:00:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1990550 Ambrx Biopharma Inc. AMAM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1376847 J. Daniel O'connor C/O Ambrx Biopharma, Inc.
10975 N Torrey Pines Road
La Jolla CA 92037
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-10-27 50,012 $9.82 342,845 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Reflects an adjustment in connection with the holding company reorganization resulting in Ambrx Biopharma, Inc. ("Ambrx") becoming a Delaware corporation (the "Domestication"). Pursuant to the transactions contemplated by the Domestication, each Ordinary Share of the previous holding company (Ambrx Biopharma Inc., a Cayman Islands company) converted into one-seventh (1/7th) of a share of common stock of Ambrx. Represents Restricted Stock Units ("RSUs") payable in Ambrx common stock granted to the Reporting Person as previously disclosed.
  2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs. The sale is mandated by Ambrx's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The sale is being made pursuant to the Reporting Person's effective 10b5-1 plan.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.99. The Reporting Person undertakes to provide to Ambrx, any security holder of Ambrx or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.